Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of the practice in a surgical ward

Détails

ID Serval
serval:BIB_DA42F7C49330
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of the practice in a surgical ward
Titre de la conférence
39th ESCP (European Society of Clinical Pharmacy) European Symposium on Clinical Pharmacy and 13th SFPC (Société Française de Pharmacie Clinique) Congress: Clinical Pharmacy at the Front line of Innovations
Auteur(s)
Perrottet N., Bez C., Zingg T., Leung Ki E.L., Demartines N., Pannatier A.
Adresse
Lyon, France, October 21-23, 2010
ISBN
2210-7703
Statut éditorial
Publié
Date de publication
2011
Volume
33
Série
International Journal of Clinical Pharmacy
Pages
435
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Introduction The benefit of stress ulcer prophylaxis (SUP) in noncriticallyill patients has not been proved. Over-prescription of SUP isnot devoided of risks (i.e. drug-drug interactions, adverse events).This prospective study aimed to evaluate the use of proton pumpinhibitors (PPIs) for SUP in a visceral surgery ward.Materials & Methods Data collection was performed prospectivelyduring a 8-week period on patients hospitalized in a visceral surgeryward (58 beds). Patients with a PPI prescription for the treatment ofulcers, gastroesophageal reflux disease, esophagitis or epigastralgiawere excluded as well as patients hospitalized twice during the studyperiod. The American Society of Health-System Pharmacists guidelineson SUP were used to assess the appropriateness of de novo PPIprescriptions.Results Among 255 patients in the study, 138 (54.1%) received aprophylaxis with PPI, of which 86 (62.3%) were de novo PPI prescriptions.93.5% of patients received esomeprazole (according to thehospital drug formulary) mainly orally at 40 mg qd. 79.1% of patientshad no risk factors for SUP. 17.9% and 3.0% had one and two riskfactors, respectively. 95% of the patients with PPI were not hospitalizedin the intensive care unit (ICU) before their stay in the visceralsurgery ward. At discharge, PPI therapy was continued in 34.2% ofpatients with a de novo PPI prescription.Discussion & Conclusion This study highlights the over-utilizationof PPIs in non-ICU patients and the inappropriate continuation of PPIprescriptions at discharge. The PPI dosage prescribed for prophylaxiswas probably too high compared with the data of the literature.Treatment recommendations for SUP are needed to restrict PPIuse for justified indications.
Mots-clé
prescribing practice, proton pump inhibitors, stress ulcer prophylaxis,
Web of science
Création de la notice
13/05/2011 9:44
Dernière modification de la notice
03/03/2018 21:54
Données d'usage